Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis
Open Access
- 21 June 2012
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (12) , 1819-1828
- https://doi.org/10.1002/acr.21764
Abstract
Objective: To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA).Methods: Claims from employer health insurance plans were used to identify RA patients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time‐varying covariates was used to evaluate the risk of GI perforation.Results: Among 143,433 RA patients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.58–1.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.78–0.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.8–17.7] for the more sensitive definition, HR 3.9 [95% CI 2.5–5.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease‐modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation.Conclusion: GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.This publication has 21 references indexed in Scilit:
- Validation of ICD‐9‐CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patientsPharmacoepidemiology and Drug Safety, 2011
- Use of Aspirin or Nonsteroidal Anti-inflammatory Drugs Increases Risk for Diverticulitis and Diverticular BleedingGastroenterology, 2011
- Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims databaseBMC Musculoskeletal Disorders, 2010
- The incidence of gastrointestinal perforations among rheumatoid arthritis patientsArthritis & Rheumatism, 2010
- Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control studyGut, 2010
- Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleedingArthritis & Rheumatism, 2010
- Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID useBMC Gastroenterology, 2009
- Long‐term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A five‐year analysis of a large medicaid populationArthritis Care & Research, 2009
- Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populationsCurrent Medical Research and Opinion, 2008
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000